Clinuvel Pharmaceuticals Ltd (CLVLF) cash flow statement

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30

$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

Clinuvel Pharmaceuticals Ltd cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30
Stock-Based Compensation	1.59	1.30	4.07
Deferred Income Taxes	-1.28	0.64	-0.33
Change in Accounts Receivable	1.73	0.20	-2.92
Change in Inventory	1.32	1.21	-0.73
Change in Accounts Payable	-0.66	0.09	-0.31
Operating Cash Flow	13	27	24
Capital Expenditures	-1.06	-0.19	-3.65
Purchase of Investments	-158	-133	-98
Investing Cash Flow	-26	-31	-19
Dividends Paid	-1.67	-1.69	-1.59
Share Repurchases	–	-0.17	-0.50
Financing Cash Flow	-1.67	-1.87	-2.09
Foreign Exchange Rate Adjustments	10	-0.05	-0.15
Net Change in Cash	-4.15	-5.24	2.26
Free Cash Flow	12	27	20
Income Taxes Paid	16	10	10

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2026

Gross margin: 82.9%
Operating margin: 43.4%
Net margin: 36.0%
Return on equity, FY2026: 13.4%

Financial strength

Current ratio: 14.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 104.2%

Valuation

P/E ratio: 11.0
Price to sales: 3.96
Price to book: 1.35
Dividend yield: –

See a number that looks wrong?